Sharemaestro Newsreel

Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Ian Karp President and Chief Executive Officer - Vikram Karnani Chief Financial Officer - Colleen Tupper Full Conference Call Transcript Operator: Greetings, and …

Liquidia (NASDAQ:LQDA) Price Target Raised to $92.00

Bank of America has raised its price target for Liquidia (NASDAQ:LQDA) to $92.00 from $79.00, maintaining a "neutral" rating, indicating a potential 16.77% upside. This comes despite Liquidia's recent quarterly earnings showing revenue growth of 1,842.1% year-over-year to $171.68 million and net income of …

Zoetis (ZTS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Steve FrankChief Executive Officer - Kristin PeckChief Financial Officer - Wetteny Joseph TAKEAWAYS Revenue -- $2.5 billion, representing a flat result on …

Collegium gains on accelerated share buybacks (COLL:NASDAQ)

Collegium Pharmaceutical (COLL) saw its stock rise in premarket trading after announcing an accelerated share repurchase agreement with Jefferies (JEF) to buy back $50 million of its company stock. This accelerated buyback is part of a larger $150 million share repurchase program authorized by …

Equities Analysts Issue Forecasts for ETON FY2027 Earnings

Emergent Biosolutions (NYSE:EBS) Rating Increased to Hold at Zacks Research

Zacks Research upgraded Emergent BioSolutions (NYSE:EBS) to a "Hold" rating. Despite beating Q2 earnings estimates, the company faces analyst forecasts for a full-year loss, increased competition, and pricing pressure, leading to a significant impairment charge against its NARCAN franchise. The stock currently has a …

Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating

Deutsche Bank has adjusted its price target for Neurocrine Biosciences (NBIX) to $165, down from $190, while maintaining a Hold rating on the stock. This adjustment comes amidst recent news including positive Phase 4 study results for Ingrezza capsules and the initiation of a …

Montauk Brewing Company Announces New Collaboration with Morning Brew Inc.

Montauk Brewing Company, a brand under Tilray Brands, Inc., has announced a new limited-edition blonde ale called "The Morning Brew" in collaboration with Morning Brew Inc. This unique 5% ABV beer features roasted coffee beans but maintains a light and refreshing profile, distinguishing it …

Collegium Pharmaceutical launches $50M accelerated share repurchase under $150M buyback program

Collegium Pharmaceutical has initiated a $50 million accelerated share repurchase (ASR) program with Jefferies, receiving an initial 1,556,420 shares. This ASR is part of a larger $150 million board-authorized buyback program, with the final share count to be determined by the volume-weighted average price …

Collegium Announces $50 Million Accelerated Share Repurchase Program

Collegium Pharmaceutical, Inc. announced an Accelerated Share Repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock. This ASR is part of a larger $150 million share repurchase program, leaving $100 million remaining after this transaction. The company believes its …

Renaissance Technologies LLC Lowers Stake in Evolus, Inc. $EOLS

Renaissance Technologies LLC significantly reduced its stake in Evolus, Inc. (NASDAQ:EOLS) by 57.6% in the first quarter, selling 460,875 shares and retaining 339,025 shares valued at $1.39 million. Despite this, institutional investors collectively own about 90.69% of Evolus, and several other funds have recently …

Earnings Update: Harrow, Inc. (NASDAQ:HROW) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Harrow, Inc. (NASDAQ:HROW) recently released its second-quarter results, showing revenues in line with expectations at US$71m, but statutory losses increased to US$0.46 per share. Following these results, analysts have updated their forecasts, predicting revenues of US$350.7m for 2026 but cutting EPS estimates significantly to …

Haleon plc (NYSE: HLN) prices $2B multi‑tranche bond to target 2027 notes

Haleon plc announced its subsidiary, Haleon Capital LLC, has priced a $2 billion SEC-registered bond offering across three tranches maturing in 2029, 2031, and 2036, with coupons ranging from 4.625% to 5.375%. The company intends to use the net proceeds, along with cash on …

Haleon prices $2B bond, one of UK health's largest debt raises

Haleon, the UK consumer health group, has priced a $2 billion three-tranche bond offering through its subsidiary Haleon US Capital LLC. The offering aims to repurchase outstanding notes due in March 2027 and refinance debt, with the remaining proceeds for general corporate purposes. This …

Evotec (EVO) slashes 2026 outlook as losses widen and revenue drops 19%

Evotec SE reported a significant downturn in its first half of 2026 financial results, with group revenue decreasing by 19.2% to €300.1 million and net loss widening to €168.6 million. The company has consequently revised its full-year 2026 guidance downwards, now expecting revenue between …

Evotec affirms FY26 sales guidance of $667M-$714M vs estimate

Evotec has reaffirmed its full-year 2026 sales guidance, maintaining the revenue range of $667.470 million to $714.310 million. This outlook exceeds the consensus estimate of $673.750 million at the lower bound, signaling stability in its near-term financial projections. The company's decision to keep the …

Haleon prices $2bn bond offering across three tranches By Investing.com

Haleon US Capital LLC, a wholly-owned subsidiary of Haleon plc, has priced a $2 billion bond offering across three tranches, maturing in 2029, 2031, and 2036 with varying coupon rates. The offering is expected to settle on August 21, 2026, and the proceeds, guaranteed …

The Top 5 Analyst Questions From Zoetis’s Q2 Earnings Call

United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play

Talphera signals ~$200,000 annual U.S. CRRT procedures in 2027 market sizing as NEPHRO CRRT reaches 75% enrollment

Earnings Call Insights: Talphera (TLPH) Q2 2026 MANAGEMENT VIEW * “With all of our final clinical sites now activated, we have reached 75% enrollment in the NEPHRO CRRT study,” said CEO Vincent Angotti, adding, “We remain on track to complete enrollment in the NEPHRO …

BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain

Burry adds to AI shorts, says ‘Nebius is what the top of a boom looks like’

Astrid Stawiarz Michael Burry disclosed updated stock positions on Wednesday, adding to his short bets on Nebius (NBIS [https://seekingalpha.com/symbol/NBIS]), Micron (MU [https://seekingalpha.com/symbol/MU]), Oracle (ORCL [https://seekingalpha.com/symbol/ORCL]), and the iShares Semiconductor ETF (SOXX [https://seekingalpha.com/symbol/SOXX]), while increasing his long positions in Mercado Libre (MELI [https://seekingalpha.com/symbol/MELI]) and Zoetis …

214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP acquired a new position in BioAge Labs, Inc. (NASDAQ:BIOA), purchasing 214,546 shares valued at approximately $3.75 million, representing a 0.48% stake in the company. Other institutional investors like Geode Capital and Marshall Wace also increased their holdings. Despite reporting a …

Bank of America Corp DE Buys 3,556,208 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Bank of America Corp DE significantly increased its stake in BioCryst Pharmaceuticals (NASDAQ:BCRX), purchasing over 3.5 million additional shares to own 2% of the company, valued at $48.5 million. This move comes as BioCryst reported strong quarterly revenues, beating analyst estimates, and analysts maintain …

Assenagon Asset Management S.A. Buys 120,097 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Assenagon Asset Management S.A. increased its stake in BioCryst Pharmaceuticals Inc. by 51.6% in the second quarter, purchasing an additional 120,097 shares. This brings their total holdings to 353,044 shares, valued at $3.53 million. Other institutional investors have also adjusted their positions in the …

Amundi Has $352,000 Holdings in ANI Pharmaceuticals, Inc. $ANIP

Amundi significantly reduced its stake in ANI Pharmaceuticals by 93% in Q1, selling 61,159 shares and retaining 4,571 shares worth $352,000. Despite Amundi's divestment, other institutional investors like Balyasny, Rubric Capital, UBS, and Schonfeld substantially increased their positions, with institutional ownership now at 76.05%. …

Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. significantly reduced its stake in Supernus Pharmaceuticals (NASDAQ:SUPN) by 86.2% in the second quarter, selling 457,443 shares and retaining 73,175 shares valued at $3.4 million. Despite this large sale, analyst sentiment for Supernus remains generally positive, with a "Moderate Buy" …

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Amylyx Pharmaceuticals (NASDAQ:AMLX) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $25.38. Despite a recent quarterly loss that missed estimates, analysts generally maintain a positive outlook, with several increasing their price targets. Institutional investors hold a …

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has received a consensus "Moderate Buy" rating from twenty-four brokerages, with an average 12-month price target of $201.50. The company's stock opened at $156.49, has a market capitalization of $15.91 billion, and has seen significant insider selling totaling over $61 …

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts

Aquestive Therapeutics (NASDAQ:AQST) has received an average "Buy" rating from analysts, with a consensus 12-month price target of $8.50. Despite exceeding second-quarter revenue expectations, the company reported a larger-than-expected loss per share and issued full-year revenue guidance below analyst consensus. Insider selling and institutional …

Dr. Reddy's Laboratories advances Thursday, outperforms competitors

Shares of Dr. Reddy's Laboratories Ltd. (500124) increased by 0.59% to 1,206.00 Indian rupees on Thursday. This occurred during a positive trading session for the stock market, with the BSE SENSEX Index (1) rising by 0.15%. The company's shares closed 14.73% below their 52-week …

Talphera Inc (TLPH) (Q2 2026) Earnings Call Highlights: NEPHRO Study Enrollment Hits 75% as KDIGO Endorsement Expands Market Opportunity

Talphera Inc. (TLPH) announced significant progress in its Q2 2026 earnings call, with 75% enrollment in its NEPHRO CRRT study and the 2026 KDIGO guidelines now referencing nafamostat as an acceptable regional anticoagulant. The company also reported a cash balance of $17.1 million and …

What Could Eton Pharmaceuticals (ETON) Gain From The ASN 001 Licensing Deal?

Gabriele Ricci Sells 25,088 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical (NYSE:TAK) General Counsel Natalie Anne Marie Furney Sells 30,868 Shares of Stock

Takeda Pharmaceutical (NYSE:TAK) Insider Sells $392,564.70 in Stock

Agosti Marcello Pignagnoli, an insider at Takeda Pharmaceutical (NYSE:TAK), sold 22,957 shares worth $392,564.70 to cover tax obligations from vested equity awards, reducing his direct ownership by 11.48%. The company's shares are trading at $17.42 with a market cap of $55.82 billion, and analysts …